United Therapeutics Gets FDA Clearance to Begin Trial of Inhaled PAH Therapy
The FDA cleared the company to begin clinical testing of Treprostinil-Iloprost SMI, an investigational inhaled combination therapy for pulmonary arterial hypertension.
The FDA cleared the company to begin clinical testing of Treprostinil-Iloprost SMI, an investigational inhaled combination therapy for pulmonary arterial hypertension.